142 related articles for article (PubMed ID: 18992059)
21. Periodontal treatment considerations for cell transplant and organ transplant patients.
Vasanthan A; Dallal N
Periodontol 2000; 2007; 44():82-102. PubMed ID: 17474927
[No Abstract] [Full Text] [Related]
22. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Kerbauy FR; Tirapelli B; Akabane H; Oliveira JS
Bone Marrow Transplant; 2009 Jun; 43(11):883-5. PubMed ID: 19079309
[No Abstract] [Full Text] [Related]
23. [Cyclosporine dose monitorization in renal transplantation C2 vs C0].
Marcén R; Villafruela JJ
Nefrologia; 2005; 25(2):106-12. PubMed ID: 15912646
[No Abstract] [Full Text] [Related]
24. Role of interleukin-15 in umbilical cord blood transplantation.
Lin SJ; Yan DC; Lee YC; Kuo ML
Int Rev Immunol; 2008; 27(6):518-31. PubMed ID: 19065354
[TBL] [Abstract][Full Text] [Related]
25. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
26. [Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation].
Aisa Y; Mori T; Shimizu T; Tsukada Y; Kato J; Suzuki S; Suzuki N; Ikeda Y; Okamoto S
Rinsho Ketsueki; 2009 Jan; 50(1):9-15. PubMed ID: 19225223
[TBL] [Abstract][Full Text] [Related]
27. Monitoring tolerance induction.
Iacomini J
Pediatr Transplant; 2006 Feb; 10(1):5-6. PubMed ID: 16499580
[No Abstract] [Full Text] [Related]
28. Graft-versus-host disease prophylaxis: does drug dosage matter?
Socié G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):331-2. PubMed ID: 22200648
[No Abstract] [Full Text] [Related]
29. Eosinophilic cystitis following cord blood transplantation: a form of acute GVHD. A variant of hemorrhagic cystitis after hematopoietic SCT or drug-induced?
Tasaka T; Matsuhashi Y; Ohnishi H; Kubota Y
Bone Marrow Transplant; 2008 Oct; 42(7):495-6. PubMed ID: 18604241
[No Abstract] [Full Text] [Related]
30. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
Auletta JJ; Cooke KR
Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
[TBL] [Abstract][Full Text] [Related]
31. Sirolimus-related toxicity in stem cell transplantation.
Busca A; Locatelli F; Moscato D; Falda M
Biol Blood Marrow Transplant; 2005 Aug; 11(8):647-9. PubMed ID: 16041315
[No Abstract] [Full Text] [Related]
32. Pleiotropic approach to graft-versus-host disease.
El-Jawahri A; Chen YB
J Clin Oncol; 2013 Dec; 31(35):4462-4. PubMed ID: 24166516
[No Abstract] [Full Text] [Related]
33. Induction of tolerance in organ recipients by hematopoietic stem cell transplantation.
Ophir E; Reisner Y
Int Immunopharmacol; 2009 Jun; 9(6):694-700. PubMed ID: 19150657
[TBL] [Abstract][Full Text] [Related]
34. [Role of NK cell receptor-expressing cells in the regulation of GVHD and GVL].
Tanaka J
Rinsho Ketsueki; 2008 Aug; 49(8):598-606. PubMed ID: 18800608
[No Abstract] [Full Text] [Related]
35. [Transplantation. New immunosuppressive agents and new possibilities for combination therapy].
Ohlman S; Gannedahl G; Ericzon BG; Groth CG
Lakartidningen; 1992 Dec; 89(50):4347-9. PubMed ID: 1469964
[No Abstract] [Full Text] [Related]
36. Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma.
Mehta J
J Clin Oncol; 2009 Oct; 27(28):e138; author reply e139-40. PubMed ID: 19720890
[No Abstract] [Full Text] [Related]
37. [Possibility of selective induction of a GVL effect without increasing GVHD].
Akatsuka Y
Rinsho Ketsueki; 2008 Aug; 49(8):607-15. PubMed ID: 18800609
[No Abstract] [Full Text] [Related]
38. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP
Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
[TBL] [Abstract][Full Text] [Related]
39. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
40. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
